Staffing & Employment Services
Build Your Comparison
Side-by-side financial analysisStock Comparison
JOB vs CCRN vs KELYA vs TBI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Staffing & Employment Services
Staffing & Employment Services
JOB vs CCRN vs KELYA vs TBI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Staffing & Employment Services | Medical - Care Facilities | Staffing & Employment Services | Staffing & Employment Services |
| Market Cap | $25M | $426M | $417M | $212M |
| Revenue (TTM) | $88M | $1.00B | $4.13B | $1.25B |
| Net Income (TTM) | $-1M | $-99M | $-266M | $-53M |
| Gross Margin | 35.5% | 19.8% | 19.5% | 28.4% |
| Operating Margin | -1.7% | -2.1% | -1.9% | -2.6% |
| Forward P/E | — | 142.4x | 13.3x | — |
| Total Debt | $5M | $2M | $159M | $171M |
| Cash & Equiv. | $21M | $109M | $33M | $25M |
JOB vs CCRN vs KELYA vs TBI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| GEE Group, Inc. (JOB) | 100 | 41.9 | -58.1% |
| Cross Country Healt… (CCRN) | 100 | 213.8 | +113.8% |
| Kelly Services, Inc. (KELYA) | 100 | 76.1 | -23.9% |
| TrueBlue, Inc. (TBI) | 100 | 45.7 | -54.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: JOB vs CCRN vs KELYA vs TBI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
JOB carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 0.64
- Lower volatility, beta 0.64, Low D/E 10.2%, current ratio 4.12x
- Beta 0.64, current ratio 4.12x
- -1.2% margin vs CCRN's -9.8%
CCRN is the clearest fit if your priority is long-term compounding.
- -7.9% 10Y total return vs KELYA's -24.0%
KELYA is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Better valuation composite
- 2.6% yield; the other 3 pay no meaningful dividend
TBI is the clearest fit if your priority is growth exposure.
- Rev growth 3.1%, EPS growth 61.4%, 3Y rev CAGR -10.5%
- 3.1% revenue growth vs CCRN's -21.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.1% revenue growth vs CCRN's -21.6% | |
| Value | Better valuation composite | |
| Quality / Margins | -1.2% margin vs CCRN's -9.8% | |
| Stability / Safety | Beta 0.64 vs KELYA's 0.92, lower leverage | |
| Dividends | 2.6% yield; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +20.3% vs CCRN's -1.2% | |
| Efficiency (ROA) | -1.8% ROA vs CCRN's -19.8%, ROIC -4.2% vs -0.9% |
JOB vs CCRN vs KELYA vs TBI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
JOB vs CCRN vs KELYA vs TBI — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CCRN leads in 3 of 6 categories
JOB leads 1 • KELYA leads 1 • TBI leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JOB leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KELYA is the larger business by revenue, generating $4.1B annually — 46.9x JOB's $88M. JOB is the more profitable business, keeping -1.2% of every revenue dollar as net income compared to CCRN's -9.8%. On growth, KELYA holds the edge at -10.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $88M | $1.0B | $4.1B | $1.2B |
| EBITDAEarnings before interest/tax | $258,000 | -$5M | -$35M | -$10M |
| Net IncomeAfter-tax profit | -$1M | -$99M | -$266M | -$53M |
| Free Cash FlowCash after capex | $726,000 | $40M | $66M | -$60M |
| Gross MarginGross profit ÷ Revenue | +35.5% | +19.8% | +19.5% | +28.4% |
| Operating MarginEBIT ÷ Revenue | -1.7% | -2.1% | -1.9% | -2.6% |
| Net MarginNet income ÷ Revenue | -1.2% | -9.8% | -6.4% | -4.3% |
| FCF MarginFCF ÷ Revenue | +0.8% | +4.0% | +1.6% | -4.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -20.5% | -17.8% | -10.7% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | -6.0% | -2.1% | -37.5% |
Valuation Metrics
KELYA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, CCRN's 24.0x EV/EBITDA is more attractive than TBI's 174.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $25M | $426M | $417M | $212M |
| Enterprise ValueMkt cap + debt − cash | $9M | $319M | $544M | $358M |
| Trailing P/EPrice ÷ TTM EPS | -0.72x | -4.49x | -1.66x | -4.34x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 142.38x | 13.34x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 23.96x | — | 174.38x |
| Price / SalesMarket cap ÷ Revenue | 0.26x | 0.40x | 0.10x | 0.13x |
| Price / BookPrice ÷ Book value/share | 0.50x | 1.32x | 0.43x | 0.76x |
| Price / FCFMarket cap ÷ FCF | 47.21x | 10.62x | 3.66x | — |
Profitability & Efficiency
CCRN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
JOB delivers a -2.1% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-27 for CCRN. CCRN carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to TBI's 0.62x. On the Piotroski fundamental quality scale (0–9), CCRN scores 6/9 vs TBI's 4/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | -27.1% | -24.6% | -18.7% |
| ROA (TTM)Return on assets | -1.8% | -19.8% | -11.3% | -8.1% |
| ROICReturn on invested capital | -4.2% | -0.9% | -4.0% | -5.2% |
| ROCEReturn on capital employed | -4.1% | -0.8% | -4.3% | -5.3% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.10x | 0.01x | 0.16x | 0.62x |
| Net DebtTotal debt minus cash | -$16M | -$106M | $126M | $146M |
| Cash & Equiv.Liquid assets | $21M | $109M | $33M | $25M |
| Total DebtShort + long-term debt | $5M | $2M | $159M | $171M |
| Interest CoverageEBIT ÷ Interest expense | -4.91x | -37.00x | -8.78x | -46.19x |
Total Returns (Dividends Reinvested)
CCRN leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CCRN five years ago would be worth $7,617 today (with dividends reinvested), compared to $2,364 for TBI. Over the past 12 months, JOB leads with a +20.3% total return vs CCRN's -1.2%. The 3-year compound annual growth rate (CAGR) favors KELYA at -10.6% vs TBI's -27.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +14.5% | +63.4% | +41.1% | +58.6% |
| 1-Year ReturnPast 12 months | +20.3% | -1.2% | +3.0% | +3.3% |
| 3-Year ReturnCumulative with dividends | -57.3% | -52.0% | -28.6% | -61.3% |
| 5-Year ReturnCumulative with dividends | -62.9% | -23.8% | -46.1% | -76.4% |
| 10-Year ReturnCumulative with dividends | -94.5% | -7.9% | -24.0% | -64.4% |
| CAGR (3Y)Annualised 3-year return | -24.7% | -21.7% | -10.6% | -27.1% |
Risk & Volatility
Evenly matched — JOB and TBI each lead in 1 of 2 comparable metrics.
Risk & Volatility
JOB is the less volatile stock with a 0.64 beta — it tends to amplify market swings less than KELYA's 0.92 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TBI currently trades 89.7% from its 52-week high vs KELYA's 80.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.64x | 0.71x | 0.92x | 0.88x |
| 52-Week HighHighest price in past year | $0.28 | $14.99 | $14.94 | $7.78 |
| 52-Week LowLowest price in past year | $0.17 | $7.43 | $7.98 | $3.18 |
| % of 52W HighCurrent price vs 52-week peak | +82.1% | +87.9% | +80.6% | +89.7% |
| RSI (14)Momentum oscillator 0–100 | 44.3 | 77.3 | 70.7 | 70.9 |
| Avg Volume (50D)Average daily shares traded | 249K | 648K | 422K | 323K |
Analyst Outlook
CCRN leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CCRN as "Hold", KELYA as "Buy", TBI as "Buy". Consensus price targets imply 24.6% upside for KELYA (target: $15) vs -21.2% for TBI (target: $6). KELYA is the only dividend payer here at 2.60% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $11.67 | $15.00 | $5.50 |
| # AnalystsCovering analysts | — | 14 | 5 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | — | +2.6% | — |
| Dividend StreakConsecutive years of raises | 0 | 1 | 0 | 0 |
| Dividend / ShareAnnual DPS | — | — | $0.31 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.6% | +2.9% | +0.5% |
CCRN leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). JOB leads in 1 (Income & Cash Flow). 1 tied.
JOB vs CCRN vs KELYA vs TBI: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is JOB or CCRN or KELYA or TBI a better buy right now?
For growth investors, TrueBlue, Inc.
(TBI) is the stronger pick with 3. 1% revenue growth year-over-year, versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). Analysts rate Kelly Services, Inc. (KELYA) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — JOB or CCRN or KELYA or TBI?
Over the past 5 years, Cross Country Healthcare, Inc.
(CCRN) delivered a total return of -23. 8%, compared to -76. 4% for TrueBlue, Inc. (TBI). Over 10 years, the gap is even starker: CCRN returned -7. 9% versus JOB's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — JOB or CCRN or KELYA or TBI?
By beta (market sensitivity over 5 years), GEE Group, Inc.
(JOB) is the lower-risk stock at 0. 64β versus Kelly Services, Inc. 's 0. 92β — meaning KELYA is approximately 44% more volatile than JOB relative to the S&P 500. On balance sheet safety, Cross Country Healthcare, Inc. (CCRN) carries a lower debt/equity ratio of 1% versus 62% for TrueBlue, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — JOB or CCRN or KELYA or TBI?
By revenue growth (latest reported year), TrueBlue, Inc.
(TBI) is pulling ahead at 3. 1% versus -21. 6% for Cross Country Healthcare, Inc. (CCRN). On earnings-per-share growth, the picture is similar: TrueBlue, Inc. grew EPS 61. 4% year-over-year, compared to -427. 4% for Kelly Services, Inc.. Over a 3-year CAGR, KELYA leads at -5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — JOB or CCRN or KELYA or TBI?
TrueBlue, Inc.
(TBI) is the more profitable company, earning -3. 0% net margin versus -36. 0% for GEE Group, Inc. — meaning it keeps -3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CCRN leads at -0. 3% versus -2. 9% for JOB. At the gross margin level — before operating expenses — JOB leads at 33. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is JOB or CCRN or KELYA or TBI more undervalued right now?
On forward earnings alone, Kelly Services, Inc.
(KELYA) trades at 13. 3x forward P/E versus 142. 4x for Cross Country Healthcare, Inc. — 129. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KELYA: 24. 6% to $15. 00.
07Which pays a better dividend — JOB or CCRN or KELYA or TBI?
In this comparison, KELYA (2.
6% yield) pays a dividend. JOB, CCRN, TBI do not pay a meaningful dividend and should not be held primarily for income.
08Is JOB or CCRN or KELYA or TBI better for a retirement portfolio?
For long-horizon retirement investors, Kelly Services, Inc.
(KELYA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), 2. 6% yield). Both have compounded well over 10 years (KELYA: -24. 0%, TBI: -64. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between JOB and CCRN and KELYA and TBI?
These companies operate in different sectors (JOB (Industrials) and CCRN (Healthcare) and KELYA (Industrials) and TBI (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
KELYA pays a dividend while JOB, CCRN, TBI do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.